To exploit the cleavage of LDLR by BMP1 as a potential strategy to treat hypercholesterolemia, it is important to know whether other astacins are also capable of cleaving LDLR within its ligand‐binding domain. The gene discussed is LDLR; the disease is familial hypercholesterolemia.